Laurynas Karpus, Vykintas Jauniškis, and Irmantas Rokaitis, three Lithuanian innovators, have developed an AI-powered platform that generates custom enzymes from scratch. Their company, Biomatter, has pioneered the Intelligent Architecture platform, which uses machine learning, physics-based modeling, and experimental testing to design new enzymes for specific industrial and medical uses. This breakthrough has earned them a spot among the top ten Tomorrow Shapers in the European Patent Office’s 2025 Young Inventors Prize.
The platform can accelerate drug development, green chemistry, and other applications. Biomatter has partnered with biotech leaders to produce essential nutrients for infant health and develop better enzymes for gene therapy and vaccine manufacturing. The team’s goal is to make enzyme engineering faster, cheaper, and more sustainable. Their work supports the United Nations Sustainable Development Goals and has the potential to revolutionize various industries. With the enzyme market expected to grow significantly, Biomatter’s innovation is critical for a more adaptive and sustainable future. The founders encourage younger generations to build and shape the future, emphasizing that it is not set in stone, but what you make of it.